rs2304256 — TYK2 TYK2 V362F

A common missense and splicing variant in TYK2 that promotes exon 8 inclusion and mildly enhances TYK2 expression, conferring protection against multiple autoimmune diseases including SLE, rheumatoid arthritis, type 1 diabetes, and psoriasis

See your personal result for TYK2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TYK2 V362F — A Common Protective Variant in Immune Signaling

Most people have never heard of TYK2, yet this kinase sits at the crossroads of three of the most clinically important cytokine pathways in autoimmune disease. TYK211 TYK2
Tyrosine kinase 2, a member of the JAK (Janus kinase) family that couples cytokine receptor signals to downstream transcription factor activation transduces signals from IL-12, IL-23, and type I interferon receptors — the same pathways targeted by modern immunology drugs and disrupted in lupus, rheumatoid arthritis, psoriasis, and type 1 diabetes. The rs2304256 (V362F) variant is a common allele that subtly shifts how TYK2 is expressed and processed, with measurable downstream protection across this disease spectrum.

Unlike the better-known TYK2 p.Pro1104Ala variant (rs34536443), which directly impairs kinase domain activity, V362F operates through a different mechanism: it promotes the inclusion of exon 8 in the mature TYK2 transcript, which is required for TYK2 to bind its cognate cytokine receptors. Carriers of the A allele show mildly enhanced TYK2 expression in whole blood — an effect that appears, paradoxically, to dampen rather than amplify net autoimmune signaling output, possibly through enhanced regulatory signaling or feedback inhibition.

The Mechanism

rs2304256 maps to exon 8 of TYK2 at chromosome 19p13.2 (GRCh38 position 10,364,976). The variant encodes a valine-to-phenylalanine substitution at residue 362 (p.Val362Phe) in the FERM (four-point-one, ezrin, radixin, moesin) domain of TYK2, which mediates receptor binding and is essential for correct cytokine receptor coupling.

Li et al. (2020)22 Li et al. (2020) demonstrated that rs2304256 — together with the intronic variant rs12720270 in intron 7 — promotes inclusion of exon 8 in TYK2 mRNA. Since exon 8 encodes part of the FERM domain required for receptor binding, its inclusion affects receptor affinity and downstream signal calibration. The A allele at rs2304256 also acts as a cis-eQTL33 cis-eQTL
A cis-eQTL (expression quantitative trait locus) is a genetic variant that influences the expression level of a nearby gene; "cis" means the gene affected is on the same chromosome for TYK2 in whole blood, mildly increasing TYK2 transcript levels.

This mechanism is distinct from — and independent of — the pseudokinase domain variant rs34536443 (p.Pro1104Ala), which directly impairs kinase regulatory activity. The two variants affect different functional domains through different molecular mechanisms and are in weak linkage disequilibrium, meaning individuals can carry either, both, or neither protective allele.

The Evidence

The protective effects of rs2304256 are among the most replicated in TYK2 genetics. A meta-analysis by Tao et al. (2011)44 meta-analysis by Tao et al. (2011) pooling 11 studies with 21,497 cases and 22,647 controls found the A allele confers OR 0.78 (95% CI 0.70–0.87, P<0.0001) for autoimmune and inflammatory diseases. The protection follows an additive dose-response: CA heterozygotes show OR 0.70 (P<0.0001), while AA homozygotes show OR 0.64 (P=0.003) compared to CC.

For autoimmune rheumatic diseases specifically, Lee and Bae (2016)55 Lee and Bae (2016) analyzed 12 studies (16,335 patients / 30,065 controls) and found the A allele OR 0.885 overall, with a stronger protective effect in Caucasians (OR 0.822). For SLE in Caucasians specifically, the protection reaches OR 0.737 — a substantial 26% odds reduction that is statistically robust but absent in Asian populations, where A allele frequency is considerably higher and the genetic architecture of autoimmune risk differs.

The most striking single-disease evidence comes from type 1 diabetes. Pellenz et al. (2021)66 Pellenz et al. (2021) demonstrated that in a Brazilian cohort, AA homozygotes had OR 0.48 (95% CI 0.29–0.81) for T1D under a recessive model — essentially halved risk — with equivalent protection under the additive model (OR 0.47, P<0.0001). The mechanism likely involves TYK2's role in interferon-driven pancreatic beta-cell apoptosis during insulitis, the early inflammatory phase preceding T1D.

A comprehensive 2021 systematic review and meta-analysis77 2021 systematic review and meta-analysis of 34 studies across eight autoimmune conditions confirmed rs2304256's protective association as one of the most consistently observed in TYK2 genetics, spanning MS, SLE, RA, Crohn's disease, ulcerative colitis, psoriasis, RA, and T1D.

Practical Implications

The A allele at rs2304256 is common — about 28% frequency in Europeans and 46% in East Asians — making AA homozygosity a real possibility (~8% of Europeans, ~21% of East Asians). Unlike the ultra-rare P1104A allele at rs34536443, this variant's protection is accessible to a substantial portion of the general population.

For CA and AA carriers, this result is most relevant in three contexts: (1) when being evaluated for autoimmune conditions, where it provides some baseline reassurance and may contextualize immune workup thresholds; (2) when any JAK or TYK2 inhibitor therapy is being considered, since baseline TYK2 signaling differs from the population norm; and (3) when considering family risk counseling for autoimmune diseases.

Pharmacologically, deucravacitinib (Sotyktu), the FDA-approved TYK2 pseudokinase inhibitor, operates on a different domain than V362F affects — but both influence TYK2-mediated signaling. Carriers of the A allele at rs2304256 may have subtly different baseline responses to TYK2 inhibitor therapy compared to CC homozygotes, though this has not been formally studied.

Interactions

rs2304256 is one of at least four independent protective signals in the TYK2 gene. The most studied is rs34536443 (p.Pro1104Ala), which affects the pseudokinase domain and is notably rarer (~4% in Europeans). The two variants operate through independent mechanisms (splicing/expression vs. kinase domain allostery) and are additive — carriers of the A allele at rs2304256 who also carry the C allele at rs34536443 have two distinct layers of TYK2 attenuation.

The intronic variant rs12720270 is in linkage disequilibrium with rs2304256 and acts through the same exon 8 splicing mechanism; the two variants were identified together in the same functional study. rs12720356 is a third independent protective TYK2 signal.

Beyond TYK2, the protective effect of rs2304256 acts within the broader autoimmune genetic architecture that includes PTPN22 (rs2476601), CTLA4 (rs3087243), and HLA class II loci — variants that modulate T cell activation thresholds through different mechanisms. Combined protective alleles across these loci likely confer additive reductions in autoimmune disease susceptibility, though formal compound interaction studies are limited.

Drug Interactions

deucravacitinib dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

CC No TYK2 V362F Protection Normal

Common genotype without the protective TYK2 V362F allele — standard autoimmune susceptibility

The CC genotype represents the GRCh38 reference allele configuration and the population majority. It does not carry the exon 8 splicing enhancement associated with the A allele. TYK2 expression and receptor binding capacity in CC carriers follows normal parameters. Your autoimmune susceptibility from this locus is indistinguishable from the general population; other loci (HLA, PTPN22, CTLA4, TNFAIP3, and the separate TYK2 variant rs34536443) determine your individual risk profile.

The absence of protection here is not a risk factor — it simply means you do not carry this particular protective signal. The A allele at rs2304256 reduces risk; the C allele is baseline, not elevated.

AC Partial TYK2 V362F Protection Beneficial

One protective A allele — partial reduction in autoimmune disease risk

Heterozygotes at rs2304256 sit between the CC baseline and the AA fully protective genotype. The exon 8 splicing and expression effects are dosage-dependent: one copy of the A allele partially promotes exon 8 inclusion, influencing receptor binding and downstream signaling calibration. In the meta-analysis by Tao et al. (2011), CA heterozygotes showed OR 0.70 (95% CI 0.60–0.83) for autoimmune disease, consistent with a meaningful per-allele effect. For T1D specifically, the additive model applies with OR ~0.47 per A allele (Pellenz et al. 2021).

The protection appears most robust in European populations; in East Asian populations, the A allele is considerably more common (~46%), which affects the statistical power and relative risk estimation in Asian-ancestry studies.

AA Full TYK2 V362F Protection Beneficial

Two protective A alleles — strongest TYK2 V362F-mediated autoimmune protection

The AA genotype represents maximum V362F-mediated protection. Both copies of the A allele drive maximal exon 8 inclusion and the mildly enhanced TYK2 expression documented by Li et al. (2020) eQTL analysis. The functional consequence — optimized TYK2-receptor coupling for calibrated cytokine signaling — appears to reduce the probability of self-directed immune amplification across IL-12, IL-23, and type I interferon pathways.

Notably, this protection operates through a completely different mechanism from the TYK2 rs34536443 (P1104A) pseudokinase variant. If you also carry one or two C alleles at rs34536443, you have two independent layers of TYK2 modulation — at the receptor binding level (V362F) and at the kinase regulatory level (P1104A).

The V362F protective mechanism via exon 8 splicing has not been shown to compromise anti-tumor immune surveillance, in contrast to P1104A. The cancer risk trade-off observed for rs34536443 C allele carriers is not documented for rs2304256 A allele carriers in published literature.